Metastatic Castration Sensitive Prostate Cancer (MCSPC)

Clinical trials for patients with prostate cancer which has spread to other parts of the body but still respond to medical or surgical treatments that lowers testosterone. (Stage 4)

Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial

NCT Number: NCT06067269
Phase: PHASE2
Trial Summary: This phase II trial evaluates apalutamide in combination with image-guided stereotactic body radiation therapy (SBRT) for the treatment of patients with prostate cancer. Prostate cancer usually needs – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Jonsson Comprehensive Cancer Center
Acronym: HEATWAVE

Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial

NCT Number: NCT06378866
Phase: PHASE2
Trial Summary: This phase II trial studies the effects of stereotactic body radiation therapy (SBRT) and the timing of treatment with androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Mayo Clinic
Acronym: DIVINE

CV CARE: CardioVascular Care in PC Patients

NCT Number: NCT06202820
Phase: NA
Trial Summary: This research is being done to test a program to assess and manage reversible cardiovascular (CV) risk factors in participants with prostate cancer starting androgen deprivation therapy (ADT), with th – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Dana-Farber Cancer Institute
Acronym:

A Trial for a Preliminary Estimate of the Effectiveness of a Novel Theoretical Framework

NCT Number: NCT06461416
Phase: NA
Trial Summary: Aim 1: To determine the preliminary effect sizes of al ActiveHeal EST (Engage-Sustain-Triumph) Program on occupational resilience. – clinicaltrials.gov for more information and locations
* Aim 2: To determine the preliminary effect sizes of ActiveHeal ES – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Arkansas
Acronym:

Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy

NCT Number: NCT05398302
Phase: PHASE1
Trial Summary: This clinical trial studies mechanisms of resistance to 177-lutetium prostate specific membrane antigen (177Lu-PSMA) radioligand therapy using image-guided biopsies in patients with castrate-resistant – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): 858 Therapeutics, Inc.
Acronym:

Behavioral Exercise Training to Reduce Cardiovascular Disease Risk

NCT Number: NCT06237179
Phase: PHASE1|PHASE2
Trial Summary: To test the preliminary effectiveness of a home-based exercise training (ET) intervention to improve exercise capacity (VO2 peak & 6-minute walk distance [6MWD]) among prostate cancer (PC) patients – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): Virginia Commonwealth University
Acronym: EXTRA-PC

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

NCT Number: NCT06244004
Phase: PHASE2
Trial Summary: This phase II trial compares the effect of FDG-positron emission tomography (PET)-guided metastasis directed radiation therapy (MDRT) in combination with standard treatments to standard treatments alo – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): Northwestern University
Acronym:

A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

NCT Number: NCT06257758
Phase: PHASE1|PHASE2
Trial Summary: The goal of this phase 1/2 clinical trial is to investigate the safety of an investigational drug called VIO-01 when taken by people who have different types of solid tumor cancers. There are two part – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): Valerio Therapeutics
Acronym:

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

NCT Number: NCT05000294
Phase: Phase 1| Phase 2
Trial Summary: Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective tr – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): University of Florida
Acronym:

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT Number: NCT04585750
Phase: Phase 1|Phase 2
Trial Summary: This study will assess the safety, tolerability, and efficacy of multiple dose levels of PC14586 alone and in combination with pembrolizumab in participants with advanced solid tumors containing a TP5 – clinicaltrials.gov for more information and locations and locations
Clinicaltrials.gov
Trial Sponsor(s): PMV Pharmaceuticals, Inc
Acronym:

Video Education With Result Dependent dIsclosure

NCT Number: NCT05225428
Phase: Not Applicable
Trial Summary: The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Dana-Farber Cancer Institute
Acronym: VERDI

Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate Cancer

NCT Number: NCT05471414
Phase: Not Applicable
Trial Summary: The study is comparing the effect on weight of providing home-delivered whole-food, plant-based meals versus standard, general nutritional counseling to men with prostate cancer on androgen-deprivatio – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Weill Medical College of Cornell University
Acronym: WFPBD

African Cancer Genome: GMD

NCT Number: NCT05754658
Phase:
Trial Summary: he goal of this study is to develop a comprehensive characterization of genetic and molecular drivers of breast and prostate cancer in individuals of – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Fox Chase Cancer Center
Acronym:

Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy

NCT Number: NCT05869682
Phase: PHASE2
Trial Summary: This phase II trial tests how well bright white light (BWL) therapy works in reducing cancer-related fatigue and depression in patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant pa – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): City of Hope Medical Center
Acronym:

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelideâ„¢ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors

NCT Number: NCT03129139
Phase: Phase 1
Trial Summary: A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™Capsules given daily for 21 days followed by 7 days off schedule – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Minneamrita Therapeutics LLC
Acronym: Minnelide 101

The Genomic Medicine at VA Study

NCT Number: NCT04331535
Phase: Not Applicable
Trial Summary: This trial will determine the clinical effectiveness of polygenic risk score testing among patients at high genetic risk for at least one of six diseases (coronary artery disease, – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Boston VA Research Institute, Inc.
Acronym: GenoVA

A Dose Finding Study to Treat Bone Tumor(s)

NCT Number: NCT06008483
Phase: PHASE1
Trial Summary: To determine the Maximum Tolerated Dose (MTD) of CycloSam®, Samarium-153-DOTMP (Sm-153-DOTMP), a radiopharmaceutical that delivers radiation to the bone when injected, given as a tandemly administere – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): QSAM Therapeutics, Inc.
Acronym:

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician’s Choice New Hormonal Agents

NCT Number: NCT06120491
Phase: PHASE3
Trial Summary: The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician’s choice NHA relative to placebo + physician’s choice NHA by assessment of radiographic progression-free sur – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): AstraZeneca
Acronym: EvoPAR-PR01

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

NCT Number: NCT02960022
Phase: PHASE2
Trial Summary: The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the primary analysis or the study specified evaluation period.
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:

PET/CT Characterization of Treatment Resistance

NCT Number: NCT05647564
Phase: NA
Trial Summary: This study will use different types of medical imaging to assess how lesions from advanced prostate cancer become resistant to second-generation AR-targeted therapy, and how the different types of ima – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Wisconsin, Madison
Acronym:

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

NCT Number: NCT05733351
Phase: PHASE1
Trial Summary: This phase I trial tests the safety and effectiveness of vudalimab (XmAb20717) in combination with standard of care treatment abiraterone, enzalutamide, or abiraterone plus docetaxel in treating patie – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Emory University
Acronym:

Collection of Blood From Patients With Cancer

NCT Number: NCT00034216
Phase:
Trial Summary: This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and ol – clinicaltrials.gov for more information and location
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)
Acronym:

National Cancer Institute “Cancer Moonshot Biobank”

NCT Number: NCT04314401
Phase:
Trial Summary: This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The “Cancer Moonshot Biobank” is a longitudinal study. This means it collects and stores sa – clinicaltrials.gov for more information and location
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)
Acronym:

PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

NCT Number: NCT04995198
Patient Summary
Phase:
Trial Summary: PROMISE aims to create a comprehensive nationwide registry of prostate cancer patients with germline pathogenic variants by prospectively screening approximately 5,000 subjects with a confirmed prostate cancer diagnosis, either through tissue biopsy, PSA greater than 100 ng/dL and/or radiographic evidence of disease and receiving systemic therapy for prostate cancer. Patients at all stages of disease will be welcome to participate in the PROMISE Registry. – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Prostate Cancer Clinical Trials Consortium
Acronym:

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

NCT Number: NCT05864144
Phase: PHASE1|PHASE2
Trial Summary: Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cem – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Sensei Biotherapeutics, Inc.
Acronym:

Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers

NCT Number: NCT05519878
Phase: Not Applicable
Trial Summary: This clinical trial evaluates light therapy and occupational therapy in improving cancer related fatigue (CRF) patients with genitourinary cancers. Light therapy is a non-pharmacological and evidence- – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): City of Hope Medical Center|National Cancer Institute (NCI)
Acronym:

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

NCT Number: NCT05785741
Phase: Phase 1|Phase 2
Trial Summary: This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors. – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): DualityBio Inc.
Acronym:

Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments

NCT Number: NCT04705038
Phase: Not Applicable
Trial Summary: The purpose of this study is to learn how an educational intervention about orchiectomy as an alternative to medical castration for those who are already on medical castration will impact the number o – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Chicago
Acronym:

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

NCT Number: NCT05800665
Phase: PHASE1
Trial Summary: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or metastatic prostate cancer. It will also ide – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Genentech, Inc.
Acronym:

A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

NCT Number: NCT05605522
Phase: Phase 1
Trial Summary: This is a first-in-human Phase 1 clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and biodistribution of [225Ac]-FPI-2059 and [111In]-FPI-2058 – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Fusion Pharmaceuticals Inc.
Acronym:

Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test

NCT Number: NCT05629494
Phase: Phase 4
Trial Summary: Prostate cancer is the most frequently diagnosed cancer in men in the Unites States. Nearly 1 million prostate biopsy procedures are performed in the United States annually and ele – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Albany Medical College
Acronym: ADAPT-PSA

Wrist Cooling for Hot Flashes Clinical Trial

NCT Number: NCT05595213
Phase: NA
Trial Summary: This pilot randomized double blind controlled crossover study aims to determine the impact of two wrist cooling devices on symptom control of hot flashes in adult men with prostate – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Boston University
Acronym:

Improving Germline Testing in At-Risk Patients With Prostate Cancer

NCT Number: NCT05470036
Phase: Not Applicable
Trial Summary: A quality improvement initiative to improve rates of germline testing among men with prostate cancer through the use of an in-clinic educational sessi – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of California, San Diego
Acronym: IMPRINT

Social Risk Factors and Discrimination in Cancer Survivorship

NCT Number: NCT05301114
Phase: NA
Trial Summary: The objective of the proposed study is to scale social risk factor screening and referral for cancer survivors and to solidify information exchange between clinical and community s – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Medstar Health Research Institute
Acronym:

TERPS Trial for de Novo Oligometastic Prostate Cancer

NCT Number: NCT05223803
Phase: Phase 2
Trial Summary: This research is being done to determine if we can improve the outcome of prostate cancer patients who have failed primary treatment – surgery or local radiation to the prostate – – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Maryland, Baltimore
Acronym:

Methods for Increasing Genetic Testing Uptake in Michigan

NCT Number: NCT05162846
Phase: NA
Trial Summary: The primary purpose of this study is to compare three interventions, two experimental and one standard of care (usual care), to see if the experimental interventions will increase – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Michigan Rogel Cancer Center
Acronym: MiGHT

KZR-261 in Subjects With Advanced Solid Malignancies

NCT Number: NCT05047536
Phase: Phase 1
Trial Summary: A first-in-human, open-label, multicenter, Phase 1 study of KZR-261 designed to assess the safety and tolerability, preliminary anti-tumor activity, and pharmacokinetics (PK) of KZ – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Kezar Life Sciences, Inc.
Acronym:

Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring

NCT Number: NCT05054296
Phase: Phase 2
Trial Summary: This phase II trial studies how well an exercise program and continuous Fitbit monitoring work for managing metabolic syndrome and cardiovascular disease risk in patients with pros – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI)
Acronym:

COAST Therapy in Advanced Solid Tumors and Prostate Cancer

NCT Number: NCT05036226
Phase: Phase 1|Phase 2
Trial Summary: The purpose of this Phase I/II study is to determine the safety and effectiveness of up to 5 study drugs used together for the treatment of solid tumor cancers. The drugs are hydro – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Medical University of South Carolina
Acronym: COAST

Improving Care After Inherited Cancer Testing

NCT Number: NCT04763915
Phase: NA
Trial Summary: The IMPACT Study seeks to refine and evaluate the effectiveness of interventions on improving guideline-adherent cancer risk management (CRM) and family communication (FC) of genet – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Vanderbilt-Ingram Cancer Center
Acronym: IMPACT

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

NCT Number: NCT04748042
Phase: Phase 2
Trial Summary: The purpose of this study is to assess the safety and effectiveness of radiation therapy with hormone therapy (ADT) and chemotherapy as an investigational study treatment for prost – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Michigan Rogel Cancer Center
Acronym:

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

NCT Number: NCT04734730
Phase: Phase 2
Trial Summary: This phase II trial studies the effect of talazoparib with androgen deprivation therapy and abiraterone in treating castration sensitive prostate cancer patients. Talazoparib is an – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): City of Hope Medical Center|National Cancer Institute (NCI)
Acronym:

M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer

NCT Number: NCT04633252
Phase: Phase 1|Phase 2
Trial Summary: Metastatic castration sensitive and castration resistant prostate cancer (mCSPC and mCRPC) are prostate cancers that have spread to other parts of the body. Use of the drug docetax – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Acronym:

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

NCT Number: NCT04478279
Phase: Phase 1|Phase 2
Trial Summary: This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in pati – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Sapience Therapeutics
Acronym:

Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients

NCT Number: NCT04353973
Phase: NA
Trial Summary: This study aims to determine if web-based eHealth delivery of pre-test and/or post-test counseling in cancer patients and/or those at risk for cancer can provide equal or improved – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Abramson Cancer Center at Penn Medicine
Acronym: eReach

Radium-223 in Biochemically Recurrent Prostate Cancer

NCT Number: NCT04206319
Phase: Phase 2
Trial Summary: Some men who have been treated for localized prostate cancer with surgery or radiation still show signs of the disease in their blood. This is called biochemically recurrent prosta – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Acronym:

Onco-primary Care Networking to Support TEAM-based Care

NCT Number: NCT04258813
Phase: NA
Trial Summary: The proposed ONE TEAM Study is an 18-month, cluster randomized controlled trial. This study will use a sequential multiple assignment randomized trial (SMART) design with a second – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Duke University
Acronym: ONE TEAM

Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients

NCT Number: NCT03987217
Phase: Early Phase 1
Trial Summary: This trial studies how well resistance training with or without creatine monohydrate supplement works in improving body composition and health outcomes in patients with prostate ca – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Utah|National Cancer Institute (NCI)
Acronym:

Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors

NCT Number: NCT03880422
Phase: Not Applicable
Trial Summary: This trial studies how well nutrition and exercise interventions work in reducing androgen deprivation therapy-induced obese frailty in prostate cancer survivors. Individualized nu – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Roswell Park Cancer Institute
Acronym:

Evaluation of CyberKnife Stereotactic Radiotherapy in Prostate Cancer

NCT Number: NCT02016248
Phase: Not Applicable
Trial Summary: The purpose of this study is to determine the side effects and how effective CyberKnife stereotactic ablative body radiation (SABR) is in patients with prostate cancer. The CyberKn – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): MemorialCare Health System
Acronym:

[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

NCT Number: NCT00588185
Phase: Not Applicable
Trial Summary: This study will use PET scans, which is a type of x-ray test that uses a radiotracer, to see whether these scans may be better able to find places in the body where your prostate c – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Memorial Sloan Kettering Cancer Center
Acronym:

Find Your Trial

Low Risk

Intermediate Risk

High Risk

Cancer Recurrence

Non-Metastatic Castration Resistant

Metastatic Castration Sensitive

Metastatic Castration Resistant

Promise Registry - All Risk Levels

PROMISE is a nationwide registry of prostate cancer patients with inherited mutations by screening approximately 5,000 participants with a prostate cancer diagnosis. The PROMISE team is studying how these mutations affect patient outcomes.

This information is for educational purposes only and not intended as medical advice.
Patients should consult their medical doctor for advice and recommendations about specific clinical trials.

Pin It on Pinterest